

ANSWERING REVIEWERS



Dear Editor,

Please find enclosed the edited manuscript in Word format (file name: 2429-review.doc).

Title: Interferon therapy in hepatitis C leading to chronic type 1 diabetes

Author: Taiba Zornitzki, Stephen Malnick, Lyudmila Lysyy, Hilla Knobler

Name of Journal: World Journal of Gastroenterology

ESPS Manuscript NO: 10386

- 1, Names of authors have been written according to instructions
2. Title was changed and shortened
3. Author contribution have been changed according to instructions
4. Abstract was changed
5. 2 key words were added
6. Core tip was added
7. Abbreviation lists were added.
8. Comments was added
9. We rephrased several sentences throughout the manuscript

In response to reviewer No. **XXXX** comments:

1. We added a sentence referring to the rarity of reports describing INF-associated type 1 diabetes in patients treated for multiple sclerosis together with a reference (no. 33)
2. We added that the follow-up available in patients with INF-induced T1DM is limited to 4 years. However based on other data, β -cell regeneration does not occur in humans after massive damage following other insults so we presume that patients who develop INF-associated T1DM will not recover.
3. We added other new anti-viral therapies for HCV infection recently reported.
4. We added a sentence in the Discussion that in HCV patients with mild-moderate disease the natural course of their liver disease is more benign than that of type 1 diabetes, a disease with significant acute and chronic complications and shortened life expectancy.

In addition I would like to point out that I am a native English speaker, a graduate of both Oxford University and the University of London, a member of your editorial board and a reviewer for your journal. I take full responsibility for the accuracy of the English appearing in the manuscript.

Sincerely, Stephen Malnick.